Abstract:Abstract: Objectives?To analyze the clinicopathological characteristics of rectal neuroendocrine tumors (R-NENs), and evaluate the efficacy and safety of endoscopic diagnosis and treatment of rectal neuroendocrine tumors (R-NENs).?Methods?The clinical data of 76 patients with rectal neuroendocrine tumors (R-NENs) diagnosed by biopsy or surgical resection after colonoscopy from January 2010 to September 2019 were analyzed retrospectively.?Results?The tumors were located in the lower rectal segment in 32 cases (42.11%), the middle segment in 25 cases (32.89%), and the lower segment in 19 cases (25.00%). Of the 36 patients, 27 were diagnosed as rectal neuroendocrine tumors (R-NENs), 2 as stromal tumors, 6 as lipomas, and 1 as leiomyoma. 29 patients underwent endoscopic submucosal dissection (ESD), 22 patients underwent endoscopic submucosal tumor resection (EMR), and 20 patients underwent endoscopic submucosal tunnel tumor resection (STER). The other 2 cases were treated by electrocoagulation and electrocision, and the other 3 cases were not treated by the above endoscopic operation due to different reasons. Among all the patients, 69 were examined by pathology and immunohistochemistry. The results showed that G1 grade was the most common in 62 cases, accounting for 81.58% (62/76) of all these cases.?Conclusion?Most of the rectal neuroendocrine tumors are male, which are prone to occur in the middle and low rectal segments, of which G1 grade is the most common; the mature application of EUS technology can make a more accurate judgment on the nature and histological origin of the lesions, but there are also some misdiagnosis, and the final case result is the gold standard; the early G1 and G2 grade rectal neuroendocrine tumors (R-NENs) are safe and effective after endoscopic treatment. And can provide more complete pathological data.